Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Silence Therapeutics (SLN) EPS (Basic) (2020 - 2025)

Silence Therapeutics' EPS (Basic) history spans 6 years, with the latest figure at -$0.09 for Q4 2025.

  • On a quarterly basis, EPS (Basic) fell 200.0% to -$0.09 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.63, a 96.87% decrease, with the full-year FY2025 number at -$0.63, down 90.91% from a year prior.
  • EPS (Basic) hit -$0.09 in Q4 2025 for Silence Therapeutics, up from -$0.15 in the prior quarter.
  • Over the last five years, EPS (Basic) for SLN hit a ceiling of $0.09 in Q4 2024 and a floor of -$2.99 in Q2 2022.
  • Historically, EPS (Basic) has averaged -$1.18 across 5 years, with a median of -$0.25 in 2024.
  • Biggest five-year swings in EPS (Basic): tumbled 1452.63% in 2021 and later soared 166.92% in 2024.
  • Tracing SLN's EPS (Basic) over 5 years: stood at -$2.5 in 2021, then skyrocketed by 93.77% to -$0.16 in 2022, then rose by 13.69% to -$0.13 in 2023, then soared by 166.92% to $0.09 in 2024, then tumbled by 200.0% to -$0.09 in 2025.
  • Business Quant data shows EPS (Basic) for SLN at -$0.09 in Q4 2025, -$0.15 in Q3 2025, and -$0.19 in Q2 2025.